Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CEVEC and VPM Sign Exclusive License Agreement

Published: Friday, January 04, 2013
Last Updated: Friday, January 04, 2013
Bookmark and Share
Agreement on the clinical development of a novel human CMV vaccine.

CEVEC Pharmaceuticals and VPM - Vakzine Projekt Management GmbH, have announced the signing of an exclusive license agreement on VPM’s proprietary human CMV dense body technology.

CAP® Technology is based on an immortalized human cell line for vaccine and protein production developed by CEVEC for industrial use.

The serum-free suspension culture of this proprietary cell line allows for high virus yields for a broad variety of human pathogenic viruses. CAP® cells are uniquely suited to produce vaccines against challenging viral targets like human CMV.

The non-infectious dense bodies are considered to be one of the most promising new CMV vaccine approaches since they result in efficient and long-lasting immunity.

The CMV dense body project is foreseen to enter clinical development within the next 18 months.

CEVEC receives exclusive word-wide development and commercialization rights from VPM and VPM will substantially contribute by taking over development project management services for the project.

The inventor of the CMV dense body technology, Prof. Dr. Plachter, an internationally reputed CMV expert, actively supports in the project as leading scientific expert.

“With VPM we are teaming up with a very reputed development partner in the field of state-of-the art vaccines for current high-medical need diseases like human CMV. We’re very pleased that VPM and CEVEC are combining our CAP® suspension cells as the enabling production platform with VPMs unique dense body technology. I’m convinced that the dense body technology and CAP® are a perfect match and the combined efforts will substantially shorten the timeline to enter clinical phases,” stated Wolfgang Kintzel, CEO at CEVEC.

"This project shows a scientific and commercial potential untapped in the field of currently pursued viral vaccine targets," Dr. Rainer Lichtenberger, CFO/COO at CEVEC complements.

“It is a great success story in translational research for VPM and Helmholtz Centre for Infection Research that we were able to bring this early stage vaccine project from academia to industry. With the out-licensing of the CMV dense body project to CEVEC, VPM could again demonstrate that its translational business model is instrumental in developing promising vaccine candidates to a stage of maturity where they can envisage a full pharma development. Cooperating with Cevec will help this potentially live-saving vaccine to tap its full potential”, added Dr. Bernd Eisele CEO of VPM.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Completion of a “First in Human” Clinical Phase I Study Using CAP® Cells
Consortium reported safe completion of clinical study with recombinant human Alkaline Phosphatase (hRESCAP®).
Tuesday, November 05, 2013
CEVEC Signs License Agreement with Yuhan of South Korea
License will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems.
Friday, December 21, 2012
CEVEC Licenses its Proprietary Human Cell Lines to Paragon Bioservices
Paragon Bioservices to perform process development for the contract manufacturing of recombinant proteins and antibodies.
Friday, August 03, 2012
CEVEC Raises €6M to Grow CAP® Technology Based Protein and Vaccine Business
CEVEC announces closing of €6M financing round.
Tuesday, August 09, 2011
CAP Cells Suitable for Commercial Vaccine Production?
CEVEC Pharmaceuticals has announced that CAP cells produce high virus titers upon infection with influenza strains.
Wednesday, September 29, 2010
CEVEC Signs Global License Agreement for Human CAP-T Technology with Life Technologies
Both the companies will co-operate to offer optimized expression kits based on CEVEC’s proprietary CAP-T cells to the global life science research community.
Wednesday, August 18, 2010
Pevion Biotech and CEVEC Pharmaceuticals Sign Exclusive License Option Agreement
Pevion to use CEVEC’s transient CAP-T™ cell expression technology to manufacture protein antigen for vaccination against infectious disease.
Wednesday, May 26, 2010
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!